Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y

29.04.25 14:59 Uhr

Werte in diesem Artikel
Aktien

11,17 EUR 0,21 EUR 1,87%

Medifast, Inc. MED delivered first-quarter 2025 results, wherein both top and bottom lines missed the Zacks Consensus Estimate. Both net sales and earnings experienced year-over-year declines.Amid growing consumer demand for long-term health and wellness solutions, Medifast has been emphasizing the importance of personalized support through its OPTAVIA program, which offers one-on-one coaching and tailored plans.Looking ahead, Medifast is prioritizing the revitalization of its coach and customer base by introducing enhanced tools, data-driven support and new products, with a strategic focus on restoring long-term growth and profitability.Medifast’s Quarterly Performance: Key InsightsMED reported a quarterly loss of 7 cents per share, which includes an unrealized gain from its investment in LifeMD. Excluding this gain, the adjusted loss was 11 cents per share, wider than the Zacks Consensus Estimate of an adjusted loss of 7 cents. The company reported an earnings of 66 cents per share in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)MEDIFAST INC Price, Consensus and EPS Surprise MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC QuoteNet revenues of $115.7 million declined 33.8% year over year due to a drop in the number of active earning OPTAVIA coaches and missed the Zacks Consensus Estimate of $120 million. The average revenue per active earning OPTAVIA Coach was $4,556, down 1.4% year over year from $4,623. The total number of active earning OPTAVIA Coaches fell 32.8% to 25,400 from 37,800 in the year-ago quarter, due to continued challenges in customer acquisition.MED’s Margin & Cost DetailsGross profit was $84.2 million, down 33.8% year over year on lower revenues. The gross margin was 72.8%, flat year over year. We expected gross profit to be $83.7 million in the first quarter.Selling, general and administrative expenses (SG&A) fell 28.4% year over year to $85.5 million. This decrease was primarily caused by a $22.4 million reduction in OPTAVIA coach compensation due to lower volume, a $3 million decline in market research and investment costs related to medically supported weight loss that were incurred in the first quarter of 2024 but did not recur this quarter, a $2.5 million decrease in employee compensation and a $1.3 million reduction in credit card fees.As a percentage of revenues, SG&A expenses increased 560 basis points (bps) to 73.9%, attributed to approximately 440 bps of deleverage on fixed costs due to lower sales volume and 200 bps from company-led marketing efforts, also impacted by lower sales volumes. These factors were partially offset by a 170-bps benefit from the absence of market research and investment costs that were incurred in the prior-year quarter.The loss from operations declined 115.9% to $1.3 million. The operating margin contracted 340 basis points year over year, reaching 1.1%.Medifast’s Financial Health SnapshotMED concluded the quarter with cash, cash equivalents and investments of $164.6 million, no debt (as of March 31, 2025), and total shareholders’ equity of $211 million.Sneak Peek Into MED’s 2025 OutlookThe company expects second-quarter 2025 revenues between $85 million and $105 million, with the bottom line ranging from a loss of 55 cents to break-even. This Zacks Rank #3 (Hold) company’s shares have lost 20.2% in the past three months compared with the industry’s 1.7% decline.Image Source: Zacks Investment ResearchKey PicksUnited Natural Foods, Inc. UNFI distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The consensus estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1.9% and 485.7%, respectively, from the year-ago figures. UNFI delivered a trailing four-quarter earnings surprise of 408.7%, on average.Utz Brands UTZ engages in the manufacture, marketing and distribution of snack foods in the United States and presently carries a Zacks Rank of 2. UTZ delivered a trailing four-quarter earnings surprise of 8.8%, on average.The Zacks Consensus Estimate for Utz Brands’ current financial-year sales and earnings indicates growth of 1.4% and 10.4%, respectively, from the year-ago numbers.Post Holdings, Inc. POST operates as a consumer-packaged goods holding company in the United States and internationally. It presently carries a Zacks Rank of 2. Post Holdings delivered a trailing four-quarter earnings surprise of 22.3%, on average.The Zacks Consensus Estimate for Post Holdings’ current financial-year sales and earnings indicates growth of 0.3% and 2.2%, respectively, from the year-ago numbers.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Natural Foods, Inc. (UNFI): Free Stock Analysis Report Post Holdings, Inc. (POST): Free Stock Analysis Report MEDIFAST INC (MED): Free Stock Analysis Report Utz Brands, Inc. (UTZ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Medifast und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Medifast

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Medifast

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Medifast Inc.

Wer­bung

Analysen zu Medifast Inc.

DatumRatingAnalyst
15.09.2017Medifast BuyD.A. Davidson & Co.
07.11.2014Medifast In-lineImperial Capital
25.09.2006Update Medifast Inc.: OutperformRyan, Beck & Co
16.03.2005Update Medifast Inc.: HoldSeidler
DatumRatingAnalyst
15.09.2017Medifast BuyD.A. Davidson & Co.
25.09.2006Update Medifast Inc.: OutperformRyan, Beck & Co
DatumRatingAnalyst
07.11.2014Medifast In-lineImperial Capital
16.03.2005Update Medifast Inc.: HoldSeidler
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Medifast Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen